Short answer
AGIOS PHARMACEUTICALS, INC. (AGIO) filed its Q1 2026 10-Q quarterly report on Apr 29, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $21M (up 137.7% year over year) with net income of −$99M.
Q1 2026 key financials · XBRL
- Revenue
- $21M
- +137.7% YoY
- Net income
- −$99M
- −11.0% YoY
- Operating margin
- -530.3%
- EPS (diluted)
- −$1.69
- −9.0% YoY
Source: XBRL data from the AGIOS PHARMACEUTICALS, INC. (AGIO) Q1 2026 10-Q on SEC EDGAR. USD.
AGIOS PHARMACEUTICALS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- AQVESME™ U.S. launch in late January 2026 created commercialization risk, including prescribing barriers from its FDA-required REMS
- Product safety risk heightened by AQVESME™ boxed warning for potential hepatocellular injury
- Mitapivat development risk centers on pending approvals for thalassemia in the EU and SCD in the United States
- Revenue concentration risk, with PYRUKYND® and AQVESME™ generating $20.7 million in first-quarter 2026 net product revenue
- Licensing obligation risk includes up to $130.0 million in potential Alnylam development and regulatory milestones plus tiered royalties
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AGIOS PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.